RT Book, Section
A1 Glogau, Richard G.
A2 Kang, Sewon
A2 Amagai, Masayuki
A2 Bruckner, Anna L.
A2 Enk, Alexander H.
A2 Margolis, David J.
A2 McMichael, Amy J.
A2 Orringer, Jeffrey S.
SR Print(0)
ID 1161348210
T1 Botulinum Toxin
T2 Fitzpatrick's Dermatology, 9e
YR 2019
FD 2019
PB McGraw-Hill Education
PP New York, NY
SN 9780071837798
LK dermatology.mhmedical.com/content.aspx?aid=1161348210
RD 2024/04/19
AB When  Drs.  Jean  and  Alastair  Carruthers  made  the  critical  leap  from  ophthalmologist  Dr.  Alan  Scott’s  seminal  use  of  botulinum  as  an  alternative  to  strabismus  surgery  to  the  cosmetic  use  of  the  toxin  to  treat  the  glabellar  frown  lines,  no  one  could  have  predicted  the  explosive  growth  of  this  agent  in  the  commercial  market.1  On  April  15,  2002,  the  US  Food  and  Drug  Administration  (FDA)  approved  Allergan,  Inc.’s  Botox  Cosmetic*  (botulinum  toxin  type  A)  for  “temporary  improvement  in  the  appearance  of  moderate-to-severe  glabellar  lines  in  adult  men  and  women  65  or  younger.”  This  was  the  first  elective  cosmetic  indication  for  which  any  commercially  available  botulinum  toxin  in  the  US  market  had  been  approved.